

## Trulance<sup>™</sup> (plecanatide) – New Drug Approval

- On January 19, 2017, <u>Synergy Pharmaceuticals announced</u> the <u>FDA approval</u> of <u>Trulance</u> (plecanatide) for the treatment of chronic idiopathic constipation (CIC) in adults.
- CIC is a complex, functional GI disorder defined by symptoms including fewer than three bowel
  movements a week and hard-to-pass or incomplete bowel movements, for which there is no
  identifiable cause. CIC affects approximately 33 million Americans and an estimated 14% of the
  global population.
- Trulance is a guanylate cyclase-C (GC-C) agonist that replicates the function of uroguanylin, an endogenous human gastrointestinal (GI) peptide. Activation of GC-C results in increased intestinal fluid and accelerated transit.
- The safety and efficacy of Trulance were based on data from two, 12- week clinical studies of 1,775 patients randomly assigned to placebo or Trulance.
  - Participants receiving Trulance were more likely to experience improvement in the frequency of complete spontaneous bowel movements than those receiving placebo (Trulance: 21% for both studies; placebo: 10% and 13% for studies 1 and 2, respectively; p < 0.005 for both studies).</li>
  - Patients taking Trulance also had improvements in stool frequency and consistency and straining,
- Trulance carries a boxed warning for risk of serious dehydration in pediatric patients.
- Trulance is contraindicated in patients < 6 years of age due to the risk of serious dehydration and in patients with known or suspected mechanical GI obstruction. Diarrhea is listed as a warning and precaution of Trulance.
- The most common adverse event (≥ 2%) with Trulance use was diarrhea.
- The recommended dose of Trulance is 3 mg orally once daily without regard to food.
  - For adult patients with swallowing difficulties, Trulance tablets can be crushed and administered orally either in applesauce or with water or administered with water via a nasogastric or gastric feeding tube. Mixing Trulance crushed tablets in other soft foods or in other liquids has not been tested.
- Synergy Pharmaceuticals plans to launch Trulance in the first quarter of 2017 as 3 mg tablets.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.